LAVA Therapeutics (LVTX) has decided to cancel the Extraordinary General Meeting of Shareholders scheduled to occur on September 30, 2025 to consider and approve certain matters related to the Company’s previously announced transaction with XOMA Royalty Corporation (XOMA), pursuant to which XOMA made an offer to purchase all of the issued and outstanding common shares in the capital of the Company. The Company is canceling the EGM to continue discussions with XOMA concerning the terms of the Transaction, including the Company’s estimated cash forecast and the consideration payable to the Company’s shareholders in the Transaction. Both the Company and XOMA Royalty remain committed to completing the Transaction. The EGM is expected to be reconvened by early November 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LVTX:
- Lava Therapeutics Reports Q2 2025 Financial Results
- LAVA Therapeutics Announces Acquisition by XOMA Corporation
- Lava Therapeutics reports Q2 EPS (32c) vs. (31c) last year
- Hold Rating on XOMA’s Acquisition of LAVA Therapeutics: Valuation and Risks Assessed
- Lava Therapeutics downgraded to Hold from Buy at Jefferies